Content about Gemcitabine

July 24, 2013

Mylan has settled with the makers of a drug used to treat cancer in a patent-infringement lawsuit, the generic drug maker said.

PITTSBURGH — Mylan has settled with the makers of a drug used to treat cancer in a patent-infringement lawsuit, the generic drug maker said Wednesday.

Mylan said it had entered an agreement with Pfizer, Genentech and OSI that would allow their suit against Mylan over the drug Tarceva (erlotinib) to be dismissed. All other terms and conditions of the settlement are confidential, and the agreement is subject to Department of Justice and Federal Trade Commission review, Mylan said.

August 9, 2011

The Food and Drug Administration has approved a generic chemotherapy drug made by Hospira, the drug maker said.

LAKE FOREST, Ill. — The Food and Drug Administration has approved a generic chemotherapy drug made by Hospira, the drug maker said.

Hospira announced the approval of gemcitabine injection in the 200-mg, 1-g and 2-g formulations and plans to launch the drug in September. The drug is a generic version of Eli Lilly's Gemzar.

Various versions of the drug had sales of $750 million in 2010, according to Hospira.

February 9, 2011

Women with ovarian cancer who received a drug made by Genentech lived longer without their disease becoming worse, according to a late-stage clinical trial.

SOUTH SAN FRANCISCO, Calif. — Women with ovarian cancer who received a drug made by Genentech lived longer without their disease becoming worse, according to a late-stage clinical trial.

Genentech, part of Swiss drug maker Roche, announced results from its phase-3 “OCEANS” study, in which women with recurring ovarian cancer received Avastin (bevacizumab) with gemcitabine and carboplatin, both chemotherapy drugs, followed by use of Avastin alone.

January 26, 2011

Generic drug makers Teva Pharmaceutical Industries and APP Pharmaceuticals have launched their version of a chemotherapy drug, the two companies said Wednesday.

JERUSALEM — Generic drug makers Teva Pharmaceutical Industries and APP Pharmaceuticals have launched their version of a chemotherapy drug, the two companies said Wednesday.

Teva and APP launched gemcitabine hydrochloride injfection in 200-mg and 1-g single-dose vials. The drug is a version of Eli Lilly’s Gemzar, which had sales of about $785 million in the United States in 2010, according to IMS Health. The drug is used to treat cancers of the lungs, pancreas, breasts and ovaries.

January 25, 2011

John Johnson is bidding Eli Lilly adieu.

INDIANAPOLIS — John Johnson is bidding Eli Lilly adieu.

Johnson, who served as SVP and president of the drug maker's oncology business — whose portfolio includes Alimta (pemetrexed) and Gemzar (gemcitabine hydrochloride) — resigned, effective Jan. 28. Johnson is taking on the chief executive role at specialty biopharmaceutical company Savient, effective Jan. 31. Savient is best known for its chronic gout treatment Krystexxa (pegloticase), which received regulatory approval in September 2010.

November 15, 2010

Generic injectable drug maker Hospira has launched a version of a chemotherapy drug, the company...

LAKE FOREST, Ill. Generic injectable drug maker Hospira has launched a version of a chemotherapy drug, the company said Monday.

 

Hospira announced the launch of gemcitabine hydrochloride in 2-g vials, a generic version of Eli Lilly’s Gemzar.

 

 

Gemzar had sales of nearly $750 million in 2009, according to Hospira.

 

May 16, 2010

The cancer drug arm of Eli Lilly plans to show data from more than 50...

March 17, 2010

Drugs stolen from an Eli Lilly warehouse in Connecticut Sunday unlikely are to make it...

January 18, 2010

The Food and Drug Administration has extended its review period for a lung cancer drug...

January 4, 2010

A maker of generic injectable drugs is involved in a patent infringement suit over a...